Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.83 |
| ▸ | NAAA | Q02083 | 1/20 | 0.77 |
| ▸ | FAAH | O00519 | 4/20 | 0.71 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.67 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.64 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10149475 | 1.00 | CASP2 (0.83) | CASP2NAAAFAAHDNM1EPHX1 | |
| SCHEMBL890027 | 1.00 | CASP2 (0.83) | CASP2NAAAFAAHDNM1EPHX1 | |
| SCHEMBL13335016 | 1.00 | CASP2 (0.83) | CASP2NAAAFAAHDNM1EPHX1 | |
| SCHEMBL890028 | 1.00 | CASP2 (0.83) | CASP2NAAAFAAHDNM1EPHX1 | |
| SCHEMBL7695217 | 1.00 | CASP2 (0.83) | CASP2NAAAFAAHDNM1EPHX1 | |
| SCHEMBL890024 | 1.00 | CASP2 (0.83) | CASP2NAAAFAAHDNM1EPHX1 | |
| SCHEMBL890026 | 1.00 | CASP2 (0.83) | CASP2NAAAFAAHDNM1EPHX1 | |
| SCHEMBL890029 | 1.00 | CASP2 (0.83) | CASP2NAAAFAAHDNM1EPHX1 | |
| SCHEMBL21233150 | 1.00 | CASP2 (0.83) | CASP2NAAAFAAHDNM1EPHX1 | |
| SCHEMBL17167933 | 1.00 | CASP2 (0.83) | CASP2NAAAFAAHDNM1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005051365-A1 | COMPOSITION AND DEVICE FOR FACILITATING VENIPUNCTURE | MEDIS S.R.L. (IT) | 2005-06-09 | — | — | WO | claimed |
| US-20120009222-A1 | MODULATION OF THE IMMUNE RESPONSE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-01-12 | — | — | US | disclosed |
| WO-2010062322-A2 | MODULATION OF THE IMMUNE RESPONSE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-06-03 | — | — | WO | disclosed |
| WO-2005051365-A1 | COMPOSITION AND DEVICE FOR FACILITATING VENIPUNCTURE | MEDIS S.R.L. (IT) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009222-A1 | MODULATION OF THE IMMUNE RESPONSE | FCGRT, MYD88, C3AR1 | CASP2 2840/4885NAAA 789/4885FAAH 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.